Tetragon Partners GP Ltd

GRAND CAYMAN, null · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$757.5M2026 Q3+ $8.5M options (notional, not included)
Positions37
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.79.8%

Tetragon Partners GP Ltd reported 37 positions worth $757.5M as of September 30, 2026 (13F filed November 16, 2026). Largest holding: PATH (54.5%). Biggest move: add PATH ($19.9M).

10 / 37 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 PATHUiPath$417.3M54.48%32,500,000——+2.3%
▸ 2 KGEIKolibri Global Energy$42.3M5.52%6,834,504———
▸ 3 SLNSilence Therapeutics$26.6M3.48%2,436,051———
▸ 4 PHVSPharvaris N.V.$26.6M3.47%838,247——+2.3%
▸ 5 IONSIonis Pharmaceuticals$19.7M2.57%440,930——-37.3%
▸ 6 AUTLAutolus Therapeutics$18.4M2.41%9,500,000——-39.7%
▸ 7 ARWRArrowhead Pharmaceuticals$17.3M2.26%264,040——-32.5%
▸ 8 LYFTLyft$15.0M1.96%1,000,000——+12.2%
▸ 9 WKWorkiva$15.0M1.96%225,000——+2.4%
▸ 10 MBXMBX Biosciences$12.9M1.69%220,647——-9.4%

Pro Feature

The remaining 27 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Tetragon Partners GP Ltd hold as of Q3 2026?

Tetragon Partners GP Ltd reported 37 positions worth $757.5M in its Q3 2026 13F filing. Largest positions: PATH (54.5%), KGEI (5.5%), SLN (3.5%), PHVS (3.5%) and IONS (2.6%).

What did Tetragon Partners GP Ltd buy in Q3 2026?

New positions: NBIX, AXSM, UBER, ANTX and GLUE (6 in all). Added to: PATH, SLN, PHVS, IONS and ARWR (17 in all).

What did Tetragon Partners GP Ltd sell in Q3 2026?

Reduced: ANNX, RLAY, WK, WBD and TECX. Sold out entirely: AXSM, AMLX, ACAD, RARE and CUE BIOPHARMA INC (8 in all).

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.